Anti-VEGF therapies improve parameters, such as OS, PFS and ORR, but they also bring about various adverse effects, ranging from frequent events, such as hypertension and proteinuria, to less frequent ones, such as impaired wound healing, gastrointestinal perforation, hemorrhage and thrombosis, reversible posterior leukoencephalopathy, cardiac impairment, and endocrine dysfunction. The gene discussed is VEGFA; the disease is Hypertension.